The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Revision Applications for the U.S.-South Africa Program for Collaborative Biomedical Research (R01)
The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (R01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.
Companion FOA: RFA-AI-16-083, Revision Applications for U.S.-South Africa Program for Collaborative Biomedical Research (U01)
- Letter of Intent Due Date(s): February 28, 2017
- Application Due Date(s): March 28, 2017
- AIDS Application Due Date(s): March 28, 2017
RFA-AI-16-082 Expiration Date March 29, 2017
Current U.S. and South African awardees through RFA-AI-14-009 as well as South African scientists with direct NIH funding may apply for supplementary funds. To further the objectives of this FOA, applicants are highly encouraged to include scientists at South African HDIs and other South African Universities of Technology and/or scientists from the South African Black, Coloured or Indian population groups as collaborators.
Application budgets are limited to $250,000 per year in total costs for up to two years. Applicants must have at least one year of funding remaining on their grant at the time of submission.
A minimum of 67% of the total cost budget should be apportioned to activities that will be conducted in South Africa.